|
1
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wienholds E and Plasterk RH: MicroRNA
function in animal development. FEBS Lett. 579:5911–5922. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Rane S, He M, Sayed D, Vashistha H,
Malhotra A, Sadoshima J, Vatner DE, Vatner SF and Abdellatif M:
Downregulation of miR-199a derepresses hypoxia-inducible
factor-1alpha and Sirtuin 1 and recapitulates hypoxia
preconditioning in cardiac myocytes. Circ Res. 104:879–886. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Xie H, Lim B and Lodish HF: MicroRNAs
induced during adipogenesis that accelerate fat cell development
are downregulated in obesity. Diabetes. 58:1050–1057. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Iorio MV and Croce CM: MicroRNA
dysregulation in cancer: Diagnostics, monitoring and therapeutics.
A comprehensive review. EMBO Mol Med. 4:143–159. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Hu M, Xia M, Chen X, Lin Z, Xu Y, Ma Y and
Su L: MicroRNA-141 regulates Smad interacting protein 1 (SIP1) and
inhibits migration and invasion of colorectal cancer cells. Dig Dis
Sci. 55:2365–2372. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xu L, Li Q, Xu D, Wang Q, An Y, Du Q,
Zhang J, Zhu Y and Miao Y: hsa-miR-141 downregulates TM4SF1 to
inhibit pancreatic cancer cell invasion and migration. Int J Oncol.
44:459–466. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Chen B, Huang T, Jiang J, Lv L, Li H and
Xia S: miR-141 suppresses proliferation and motility of gastric
cancer cells by targeting HDGF. Mol Cell Biochem. 388:211–218.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Tamagawa S, Beder LB, Hotomi M, Gunduz M,
Yata K, Grenman R and Yamanaka N: Role of miR-200c/miR-141 in the
regulation of epithelial-mesenchymal transition and migration in
head and neck squamous cell carcinoma. Int J Mol Med. 33:879–886.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Weir GC and Bonner-Weir S: Sleeping islets
and the relationship between β-cell mass and function. Diabetes.
60:2018–2019. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Maris M, Ferreira GB, D'Hertog W, Cnop M,
Waelkens E, Overbergh L and Mathieu C: High glucose induces
dysfunction in insulin secretory cells by different pathways: A
proteomic approach. J Proteome Res. 9:6274–6287. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chatterjee S and Davies MJ: Current
management of diabetes mellitus and future directions in care.
Postgrad Med J. 91:612–621. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Kaul K, Apostolopoulou M and Roden M:
Insulin resistance in type 1 diabetes mellitus. Metabolism.
64:1629–1639. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sergienko VA: Insulin resistance and
arterial stiffness in patients with diabetes mellitus type 2 and
cardiovascular autonomic neuropathy. Zh Nevrol Psikhiatr Im S S
Korsakova. 114:11–15. 2014.(In Russian). PubMed/NCBI
|
|
15
|
Polsky S and Ellis SL: Obesity, insulin
resistance, and type 1 diabetes mellitus. Curr Opin Endocrinol
Diabetes Obes. 22:277–282. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Fakhrzadeh H, Sharifi F, Alizadeh M,
Arzaghi SM, Tajallizade-Khoob Y, Tootee A, Alatab S, Mirarefin M,
Badamchizade Z and Kazemi H: Relationship between insulin
resistance and subclinical atherosclerosis in individuals with and
without type 2 diabetes mellitus. J Diabetes Metab Disord.
15:412016. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Iversen DS, Støy J, Kampmann U, Voss TS,
Madsen LR, Møller N and Ovesen PG: Parity and type 2 diabetes
mellitus: A study of insulin resistance and β-cell function in
women with multiple pregnancies. BMJ Open Diabetes Res Care.
4:e0002372016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ao C, Huo Y, Qi L, Xiong Z, Xue L and Qi
Y: Pioglitazone suppresses the lipopolysaccharide-induced
production of inflammatory factors in mouse macrophages by
inactivating NF-kappaB. Cell Biol Int. 34:723–730. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wan H, Yuan Y, Qian A, Sun Y and Qiao M:
Pioglitazone, a PPARgamma ligand, suppresses NFkappaB activation
through inhibition of IkappaB kinase activation in cerulein-treated
AR42J cells. Biomed Pharmacother. 62:466–472. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Collino M, Aragno M, Mastrocola R,
Gallicchio M, Rosa AC, Dianzani C, Danni O, Thiemermann C and
Fantozzi R: Modulation of the oxidative stress and inflammatory
response by PPAR-gamma agonists in the hippocampus of rats exposed
to cerebral ischemia/reperfusion. Eur J Pharmacol. 530:70–80. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Lin L, Liang H, Wang Y, Yin X, Hu Y, Huang
J, Ren T, Xu H, Zheng L and Chen X: microRNA-141 inhibits cell
proliferation and invasion and promotes apoptosis by targeting
hepatocyte nuclear factor-3β in hepatocellular carcinoma cells. BMC
Cancer. 14:8792014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Xue J, Niu YF, Huang J, Peng G, Wang LX,
Yang YH and Li YQ: miR-141 suppresses the growth and metastasis of
HCC cells by targeting E2F3. Tumour Biol. 35:12103–12107. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu Y, Ding Y, Huang J, Wang S, Ni W, Guan
J, Li Q, Zhang Y, Ding Y, Chen B and Chen L: MiR-141 suppresses the
migration and invasion of HCC cells by targeting Tiam1. PLoS One.
9:e883932014. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lee CS, Sund NJ, Vatamaniuk MZ,
Matschinsky FM, Stoffers DA and Kaestner KH: Foxa2 controls Pdx1
gene expression in pancreatic beta-cells in vivo. Diabetes.
51:2546–2551. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baroukh N, Ravier MA, Loder MK, Hill EV,
Bounacer A, Scharfmann R, Rutter GA and Van Obberghen E:
MicroRNA-124a regulates Foxa2 expression and intracellular
signaling in pancreatic beta-cell lines. J Biol Chem.
282:19575–19588. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Yu T, Lu XJ, Li JY, Shan TD, Huang CZ,
Ouyang H, Yang HS, Xu JH, Zhong W, Xia ZS and Chen QK:
Overexpression of miR-429 impairs intestinal barrier function in
diabetic mice by down-regulating occludin expression. Cell Tissue
Res. 366:341–352. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yang X, Tao Z, Zhu Z, Liao H, Zhao Y and
Fan H: MicroRNA-593-3p regulates insulin-promoted glucose
consumption by targeting Slc38a1 and CLIP3. J Mol Endocrinol.
57:211–222. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Chen Y, Tian L, Wan S, Xie Y, Chen X, Ji
X, Zhao Q, Wang C, Zhang K, Hock JM, et al: MicroRNA-17-92 cluster
regulates pancreatic beta-cell proliferation and adaptation. Mol
Cell Endocrinol. 437:213–223. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhuo S, Yang M, Zhao Y, Chen X, Zhang F,
Li N, Yao P, Zhu T, Mei H, Wang S, et al: MicroRNA-451 negatively
regulates hepatic glucose production and glucose homeostasis by
targeting glycerol kinase-mediated gluconeogenesis. Diabetes.
65:3276–3288. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Fu X, Dong B, Tian Y, Lefebvre P, Meng Z,
Wang X, Pattou F, Han W, Wang X, Lou F, et al: MicroRNA-26a
regulates insulin sensitivity and metabolism of glucose and lipids.
J Clin Invest. 125:2497–2509. 2015. View
Article : Google Scholar : PubMed/NCBI
|
|
32
|
Wang B, Koh P, Winbanks C, Coughlan MT,
McClelland A, Watson A, Jandeleit-Dahm K, Burns WC, Thomas MC,
Cooper ME and Kantharidis P: miR-200a prevents renal fibrogenesis
through repression of TGF-β2 expression. Diabetes. 60:280–287.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kanatani Y, Usui I, Ishizuka K, Bukhari A,
Fujisaka S, Urakaze M, Haruta T, Kishimoto T, Naka T and Kobayashi
M: Effects of pioglitazone on suppressor of cytokine signaling 3
expression: Potential mechanisms for its effects on insulin
sensitivity and adiponectin expression. Diabetes. 56:795–803. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Iwata M, Haruta T, Usui I, Takata Y,
Takano A, Uno T, Kawahara J, Ueno E, Sasaoka T, Ishibashi O and
Kobayashi M: Pioglitazone ameliorates tumor necrosis
factor-alpha-induced insulin resistance by a mechanism independent
of adipogenic activity of peroxisome proliferator-activated
receptor-gamma. Diabetes. 50:1083–1092. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hu SH, Jiang T, Yang SS and Yang Y:
Pioglitazone ameliorates intracerebral insulin resistance and
tau-protein hyperphosphorylation in rats with type 2 diabetes. Exp
Clin Endocrinol Diabetes. 121:220–224. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Sebastiani G, Po A, Miele E, Ventriglia G,
Ceccarelli E, Bugliani M, Marselli L, Marchetti P, Gulino A,
Ferretti E and Dotta F: MicroRNA-124a is hyperexpressed in type 2
diabetic human pancreatic islets and negatively regulates insulin
secretion. Acta Diabetol. 52:523–530. 2015. View Article : Google Scholar : PubMed/NCBI
|
